IEEE Pulse | 2021
The Search for a Drug to End Alzheimer’s
Abstract
On November 6, 2020, researchers who have been laboring to find a drug that will treat Alzheimer’s disease (AD) dialed in to a public meeting of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee. The committee would review drug trials of Biogen’s aducanumab, and conclude with a vote on the drug’s safety and efficacy in treating AD. The independent advisors’ decision wouldn’t be the official one for aducanumab, but their vote usually mirrors the final FDA decision.